Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer

Sakaguchi, Kôichi; Nakatsukasa, Katsuhiko; Taguchi, Tetsuya

doi:10.21873/anticanres.11252

Cited by 6 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S-1 (Taiho Pharmaceutical Company), an oral combination of the fluoropyrimidine tegafur, the DPD inhibitor gimeracil, and oteracil potassium, intended to reduce gastrointestinal toxicity of fluorouracil, has shown efficacy in various gastrointestinal malignancies (3)(4)(5). Phase II studies of S-1 as first-line therapy for metastatic pancreatic cancer resulted in response rates of 21.1% to 37.5% (6).…”

Section: Introductionmentioning

confidence: 99%

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Jiang

Qiao

Wang

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Advanced pancreatic cancer has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells (DC-CIK) administered with the chemotherapy (CT) S-1 in this malignancy. Consecutive patients ( = 47) with advanced pancreatic cancer were treated with either DC-CIK + S-1, DC-CIK alone, S-1 alone, or best supportive care. DC-CIK plus S-1 produced significantly longer median OS and PFS (212 and 136 days) compared with DC-CIK (128 and 85 days), CT (141 and 92 days), or supportive care only (52 and 43 days; < 0.001). After adjusting for competing risk factors, DC-CIK combined with S-1 and receipt of 2 or more cycles of DC-CIK treatment remained independent predictors of disease-free and overall survival ( < 0.05). Phenotypic analysis of PBMCs demonstrated that the CD3, CD3/CD4, and CD8/CD28 T-cell subsets were elevated ( < 0.05), while the CD3/CD8, CD3/CD16/CD56 and CD4/CD25 cell subsets were significantly decreased after DC-CIK cell therapy ( < 0.05). There were no grade 3 or 4 toxicities. In addition, the mutational frequency in cell-free tumor DNA (cfDNA) declined in 4 of 14 patients who received DC-CIK, and was associated with a more favorable survival. Treatment of advanced pancreatic cancer with combined DC-CIK infusions and S-1 was safe, resulted in favorable PFS and OS, and modulated the peripheral blood immune repertoire. .

show abstract

Section: Introductionmentioning

confidence: 99%

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Jiang

Qiao

Wang

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Several multiagent chemotherapy regimens have demonstrated modest survival benefits in the first line treatment (4). S-1 (5), an oral combination of the fluoropyrimidine tegafur, the DPD-inhibitor gimeracil, and oteracil potassium, intended to reduce gastrointestinal toxicity of fluorouracil, is commonly used in Asia for management of gastrointestinal malignancies including GC (6,7). A network meta-analysis reported that S-1 regimens were more effective than fluorouracil in advanced GC (8).…”

Section: Introductionmentioning

confidence: 99%

Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study

Qiao

Wang

Zhou

et al. 2019

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We have assessed the combination of DC-CIK with S-1 plus cisplatin chemotherapy in advanced gastric cancer (AGC) and the role of mutational analysis of circulating tumor DNA (ctDNA) and T-cell receptor (TCR) repertoire in predicting clinical outcomes. Patients and Methods: Consecutive patients (n ¼ 63) with AGC were allocated to treatment with S-1 alone, S-1 plus cisplatin, DC-CIK combined with S-1 or DC-CIK combined with S-1 plus cisplatin. The primary endpoints were progression-free survival (PFS) and overall survival (OS) at 1 year; the secondary endpoints were disease control rate and analysis of ctDNA and TCR repertoire. Results: The DC-CIK infusions were well tolerated with no serious adverse events. The disease control rates (CR þ PR þ SD) were 5.6%, 33.3%, 47.1%, and 76.9% in the S-1 alone, the S-1 plus cisplatin, DC-CIK combined with S-1 and DC-CIK combined with the S-1 plus cisplatin groups, respectively (P ¼ 0.001). After adjusting for competing risk factors, treatment with DC-CIK combined with S-1 plus cisplatin was confirmed to be an independent predictor of PFS and OS (P ¼ 0.001). A decrease in the frequency and number of mutations in ctDNA was observed in 19 patients (63.3%) following the DC-CIK infusions. Decreased ctDNA mutational frequency and restored TCR repertoire were associated with improved PFS and OS (P ¼ 0.001). Conclusions: DC-CIK combined with S-1 plus cisplatin provided a favorable PFS and OS in patients with AGC and the combination therapy was safe with tolerable toxicities. Clinical efficacy correlated with decreases in ctDNA mutational profiles and restored TCR repertoire.

show abstract

Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives

et al. 2023

View full text Add to dashboard Cite

Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer

Abstract: The response rate was 66.7%. The clinical benefit rate was 77.8%. Our study shows the efficacy and the feasibility of this combination therapy.

Cited by 6 publications

References 16 publications

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study

Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study

Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives

Contact Info

Product

Resources

About